Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > People still write in capital Letters Lol

<< Previous

Bullboard Posts

Next >>

Comment by boozehound3on Jun 03, 2019 11:31am

28 Views

Post# 29794020

RE:People still write in capital Letters Lol

well blairman as you can see from the sell off today there are some smart people out there

amarin will fall just as far as it went up if the fda wants another study and acasti, well it will kill them.

wake up and do some research

even francine is on board now

<< Previous

Bullboard Posts

Next >>

This AI stock is disrupting the event tickets monopoly